Biotech Startups

Abyrx (Orthocon) develops a materials science platform focused on therapeutic surgical devices, including water-soluble, resorbable hemostatic bone putty products such as MONTAGE. Its products are used by surgeons in orthopedic, trauma, spine, sports medicine, cranial, maxillofacial, and cardiothoracic procedures.

1 investor

Orvida Pharma develops pharmaceuticals for rare genetic skin diseases and orphan indications, with expertise spanning drug development from early discovery through FDA and EMA regulatory approval.

1 investor

1 investor

Osivax develops vaccines targeting conserved internal viral structures to provide broader and longer-lasting protection against influenza, leveraging its proprietary oligoDOM technology platform. The company originated from research co-developed with the University of Oxford and is supported by public health foundations and pharmaceutical partners.

1 investor

OssDsign develops orthopedic and spine medical devices, drawing on expertise across clinical affairs, sales, and manufacturing from leading companies like Medtronic and Boston Scientific. The company serves surgical and orthobiologic markets with a team of executives experienced in bone healing and medical device commercialization.

1 investor

Ossianix develops TXP1, a brain-selective shuttle based on a deimmunised VNAR antibody scaffold that targets TfR1 to carry therapeutic payloads across the blood-brain barrier. The company focuses on improving delivery of central nervous system therapeutics to the brain.

1 investor

1 investor

Osteal Therapeutics is a clinical-stage pharmaceutical company developing novel treatments for orthopedic infections, particularly periprosthetic joint infections. Its lead product, NEXCHANGE KIT, is a drug-device combination designed for localized antibiotic delivery to infected joint prostheses.

1 investor

Osteocentric develops orthopedic implant systems for bone fixation, including fasteners, plates, and surgical instruments that use UnifiMI mechanical integration technology. The company serves orthopedic surgeons and hospitals treating fractures and skeletal injuries.

1 investor

Oticara is a clinical-stage biopharmaceutical company developing an investigational intranasal corticosteroid therapy for chronic rhinosinusitis (CRS). Its product is a single-dose, semisolid emulsion formulation placed by an ENT physician under endoscopic guidance, targeting patients with persistent symptoms after topical therapies and sinus surgery.

1 investor

OTIF Ventures is a venture capital firm that identifies and invests in high-quality technology and life science spinouts, particularly from Oxford University, providing ongoing board-level support to portfolio companies.

1 investor

OTOFARMA is an Italian manufacturer of custom hearing aids with ISO certification, sold exclusively through partnered pharmacies. The company also offers telemedicine audiology services, positioning itself as Italy's only certified hearing aid constructor with integrated remote consultations available in over 3,000 affiliated pharmacies.

1 investor

OtoImmune is developing precision immunology products under its mOI and mOI Health brands. The page provides no further detail about the specific products, technology, or target customers.

1 investor

Ourobio develops engineered microorganisms that convert industrial byproducts into biomaterials using synthetic biology. The company targets industries seeking sustainable alternatives to petroleum-derived chemicals and materials.

1 investor

Outdefine provides a governed decisioning and execution layer for clinical trial teams, using trial-trained AI inference and workflow agents to support site feasibility ranking, study risk monitoring, and real-world evidence analysis. It sits above existing clinical systems to connect trial data, protocol rules, and outcomes for pharmaceutical and life sciences operations.

1 investor

Outlander Materials develops microbial nanocellulose through controlled fermentation, engineered for industrial-scale production and cost-efficient sustainable material applications. The company serves industries seeking high-performance bio-based alternatives to synthetic materials without compromising on performance or cost.

1 investor

1 investor

Outpost operates a "lab-in-the-loop" platform combining high-throughput experiments with machine learning to model the human microbiome and predict how drugs, food ingredients, and formulations interact with microbial ecosystems. It serves drug and ingredient R&D teams with metabolism, toxicity, efficacy, and safety screening to de-risk candidates in development.

1 investor

Overture develops precision antibody therapeutics for obesity treatment, targeting metabolic dysfunction pathways to reduce fat mass while preserving lean muscle through monthly-dosed therapeutic approaches.

1 investor

Benchling In Vivo is software for managing preclinical in vivo studies, including study design, animal randomization, data capture, and reporting across efficacy, tolerability, and survival studies. The platform consolidates animal assignment, dosing schedules, and study observations in a digital system to replace spreadsheets and paper records.

1 investor

Ovipost farms insects and worms to produce protein by converting organic waste, positioning insect farming as a sustainable protein source and upcycling solution.

1 investor

OVO Biomanufacturing offers a cloud-based software platform that helps viral vaccine manufacturers manage and reduce defective interfering particles (DIPs) to improve production yields. Using Next Generation Sequencing data, the platform guides producers to optimise DIP populations when creating working seed stocks for live attenuated and inactivated viral vaccines, with an initial focus on the influenza vaccine market.

1 investor

Ownmed Innovation is a spin-off that develops medical devices and technologies to address unmet clinical needs, taking products through preclinical studies, clinical trials, and CE certification under EU regulation 2017/745. Its focus includes ostomy care, with a device aimed at restoring continence.

1 investor

Oxford Medical Products develops medical devices, drawing on a team of biotech entrepreneurs, material scientists, polymer chemists and medical device engineers.

1 investor